Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Invest in next-gen health screening, today
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Invest in next-gen health screening, today
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Invest in next-gen health screening, today
Revealia™ makes wellness monitoring easy, offering insights into potential health risks and peace of mind for your well-being.
Revealia™ leverages mRNA-based screening to provide early insights of potential health risks.
Revealia™ leverages mRNA-based screening to provide early insights of potential health risks.
leading the future of early Screening
Patent Protected Technology
Patent Protected Technology
Experienced Leadership Team
Experienced Leadership Team
Over 3,000 Patient Samples Collected
Over 3,000 Patient Samples Collected
Nanoscale Technology + AI Insights = Groundbreaking Results
Nanoscale Technology + AI Insights = Groundbreaking Results
Innovative screening
Innovative screening
Our advanced nanoscale technology and AI analyze mRNA from a simple cheek swab, offering insights into a broad range of potential health risks, including various cancers and inflammatory conditions.
Over 3,000 Patient Samples Collected
Over 3,000 Patient Samples Collected
These samples were collected in 40 clinics in the United States according to an IRB approved clinical protocol.
World Renowned Research
World Renowned Research
Hundreds of peer-reviewed articles in renowned publications support our scientific breakthrough.
Pioneering Excellence in Product Development
Pioneering Excellence in Product Development
Cheek Swab Technology
Cheek swabs are a convenient, non-invasive method to collect cells for genetic analysis.
1
Cheek Swab Technology
Cheek swabs are a convenient, non-invasive method to collect cells for genetic analysis.
1
Cheek Swab Technology
Cheek swabs are a convenient, non-invasive method to collect cells for genetic analysis.
1
Powerful IP Protection
In 2022, our PCT Patent Pending covers a uniquely designed chip featuring 48 mRNA bio-markers, combined with our cheek swab for nanoscale screening.
2
Powerful IP Protection
In 2022, our PCT Patent Pending covers a uniquely designed chip featuring 48 mRNA bio-markers, combined with our cheek swab for nanoscale screening.
2
Powerful IP Protection
In 2022, our PCT Patent Pending covers a uniquely designed chip featuring 48 mRNA bio-markers, combined with our cheek swab for nanoscale screening.
2
Top Rated Results Lab
Our lab has the coveted and highest possible ratings with both CLIA and CAP certifications.
3
Top Rated Results Lab
Our lab has the coveted and highest possible ratings with both CLIA and CAP certifications.
3
Top Rated Results Lab
Our lab has the coveted and highest possible ratings with both CLIA and CAP certifications.
3
Medical Science + Al Expertise
Co-founder, is a renowned physician and scientist with a legacy of 56 years of accomplishments and successes in the field of medical science and biotechnology.
4
Medical Science + Al Expertise
Co-founder, is a renowned physician and scientist with a legacy of 56 years of accomplishments and successes in the field of medical science and biotechnology.
4
Medical Science + Al Expertise
Co-founder, is a renowned physician and scientist with a legacy of 56 years of accomplishments and successes in the field of medical science and biotechnology.
4
Our team is made up of leading experts in health, experienced AI technologists, and skilled operators. A CAP CLIA certified lab collects, validates and analyzes our extensive and growing patient samples.
Explore our progress and future goals. Milestones achieved, including research, development, and product rollout.
Explore our progress and future goals. Milestones achieved, including research, development, and product rollout.
IP Protection
2022
Uplisting will help scale advertising and expand disease screening capabilities.
Patents pending on nanoscale signals our Al can use to detect many types of cancer and other progressive diseases
Invented Al driven process gets nanogram quantities of cancer signals effectively analyzed for diagnostics
Over 3,000 people have already taken our cheek-swab test
October launch for direct-to- consumer cheek-swab test.
2023
Testing
2024
Uplist + Scale
Launch
2024
Invention
2019
Invention
Invented Al driven process gets nanogram quantities of cancer signals effectively analyzed for diagnostics
Invented Al driven process gets nanogram quantities of cancer signals effectively analyzed for diagnostics
IP Protection
Patents pending on nanoscale signals our Al can use to detect many types of cancer and other progressive diseases
Patents pending on nanoscale signals our Al can use to detect many types of cancer and other progressive diseases
Testing
Over 3,000 people have already taken our cheek-swab test
Over 3,000 people have already taken our cheek-swab test
Launch
October launch for direct-to- consumer cheek-swab test.
October launch for direct-to- consumer cheek-swab test.
Uplist + Scale
Uplisting will help scale advertising and expand disease screening capabilities.
Uplisting will help scale advertising and expand disease screening capabilities.
Leadership goals
Leadership goals
Marvin S. Hausman, M.D.
CSO
Immunologist and Board-Certified Urological Surgeon. He’s held prestigious appointments at NIH and UCLA Medical Center and is the creator of the mRNA Inflammatory Index.™ Marvin has 30 years of drug research and development experience with major pharmaceutical companies such as Bristol-Meyers, Mead-Johnson and E.R. Squibb. He has also founded or co-founded numerous biopharmaceutical enterprises.
Creator of the mRNA Inflammatory Index™, leading the way in advancing early screening and proactive health management.
Antonio Reyes
CEO
Executive with experience as a Founder, CEO, COO, and Director of Business Development. He has forged strategic partnerships, led expert teams, and improved operational systems to boost revenue. Antonio grew BlockScience from 4 to 42+ employees and established partnerships with renowned institutions, achieving significant sales growth. He effectively communicates vision, direction & value propositions to all stakeholders.
Redefining the future of early screening and prevention with groundbreaking innovation.
Dr. Kyle H. Ambert
CTO
PhD in Biomedical Informatics. Dr. Ambert is currently the Director of Data Science at Nike’s Consumer Data Science division. Before Nike Dr. Ambert was the Senior Deep Learning Data Scientist at Intel. His responsibilities at Intel included Data Scientist roles in Artificial Intelligence & Applied Analytics Group, Health & Life Sciences: Big Data Solutions Group and Biomedical & Big Data Research.
Bringing AI and data into biotech and genetics is our most transformative achievement.
Scott Silverman
CFO
Scott, a financial executive with 25+ years of experience, excels in SME operational and financial management. He has diverse expertise in accounting, finance, legal, and operations, including SEC regulations. As President and CEO of EverAsia Financial Group, he grew the firm internationally. Scott has raised early-stage funds, taken five companies public, and earned recognition on Entrepreneur Magazine's “Hot 100” list. He holds a Bachelor's in Finance and a Master's in Accounting.
Smart financial leadership has been key to fueling our growth and advancing our mission.
Marvin S. Hausman, M.D.
CSO
Immunologist and Board-Certified Urological Surgeon. He’s held prestigious appointments at NIH and UCLA Medical Center and is the creator of the mRNA Inflammatory Index.™ Marvin has 30 years of drug research and development experience with major pharmaceutical companies such as Bristol-Meyers, Mead-Johnson and E.R. Squibb. He has also founded or co-founded numerous biopharmaceutical enterprises.
Creator of the mRNA Inflammatory Index™, leading the way in advancing early screening and proactive health management.
Antonio Reyes
CEO
Executive with experience as a Founder, CEO, COO, and Director of Business Development. He has forged strategic partnerships, led expert teams, and improved operational systems to boost revenue. Antonio grew BlockScience from 4 to 42+ employees and established partnerships with renowned institutions, achieving significant sales growth. He effectively communicates vision, direction & value propositions to all stakeholders.
Redefining the future of early screening and prevention with groundbreaking innovation.
Dr. Kyle H. Ambert
CTO
PhD in Biomedical Informatics. Dr. Ambert is currently the Director of Data Science at Nike’s Consumer Data Science division. Before Nike Dr. Ambert was the Senior Deep Learning Data Scientist at Intel. His responsibilities at Intel included Data Scientist roles in Artificial Intelligence & Applied Analytics Group, Health & Life Sciences: Big Data Solutions Group and Biomedical & Big Data Research.
Bringing AI and data into biotech and genetics is our most transformative achievement.
Scott Silverman
CFO
Scott, a financial executive with 25+ years of experience, excels in SME operational and financial management. He has diverse expertise in accounting, finance, legal, and operations, including SEC regulations. As President and CEO of EverAsia Financial Group, he grew the firm internationally. Scott has raised early-stage funds, taken five companies public, and earned recognition on Entrepreneur Magazine's “Hot 100” list. He holds a Bachelor's in Finance and a Master's in Accounting.
Smart financial leadership has been key to fueling our growth and advancing our mission.
Marvin S. Hausman, M.D.
CSO
Immunologist and Board-Certified Urological Surgeon. He’s held prestigious appointments at NIH and UCLA Medical Center and is the creator of the mRNA Inflammatory Index.™ Marvin has 30 years of drug research and development experience with major pharmaceutical companies such as Bristol-Meyers, Mead-Johnson and E.R. Squibb. He has also founded or co-founded numerous biopharmaceutical enterprises.
Creator of the mRNA Inflammatory Index™, leading the way in advancing early screening and proactive health management.
Antonio Reyes
CEO
Executive with experience as a Founder, CEO, COO, and Director of Business Development. He has forged strategic partnerships, led expert teams, and improved operational systems to boost revenue. Antonio grew BlockScience from 4 to 42+ employees and established partnerships with renowned institutions, achieving significant sales growth. He effectively communicates vision, direction & value propositions to all stakeholders.
Redefining the future of early screening and prevention with groundbreaking innovation.
Dr. Kyle H. Ambert
CTO
PhD in Biomedical Informatics. Dr. Ambert is currently the Director of Data Science at Nike’s Consumer Data Science division. Before Nike Dr. Ambert was the Senior Deep Learning Data Scientist at Intel. His responsibilities at Intel included Data Scientist roles in Artificial Intelligence & Applied Analytics Group, Health & Life Sciences: Big Data Solutions Group and Biomedical & Big Data Research.
Bringing AI and data into biotech and genetics is our most transformative achievement.
Scott Silverman
CFO
Scott, a financial executive with 25+ years of experience, excels in SME operational and financial management. He has diverse expertise in accounting, finance, legal, and operations, including SEC regulations. As President and CEO of EverAsia Financial Group, he grew the firm internationally. Scott has raised early-stage funds, taken five companies public, and earned recognition on Entrepreneur Magazine's “Hot 100” list. He holds a Bachelor's in Finance and a Master's in Accounting.
Smart financial leadership has been key to fueling our growth and advancing our mission.
Marvin S. Hausman, M.D.
CSO
Immunologist and Board-Certified Urological Surgeon. He’s held prestigious appointments at NIH and UCLA Medical Center and is the creator of the mRNA Inflammatory Index.™ Marvin has 30 years of drug research and development experience with major pharmaceutical companies such as Bristol-Meyers, Mead-Johnson and E.R. Squibb. He has also founded or co-founded numerous biopharmaceutical enterprises.
Creator of the mRNA Inflammatory Index™, leading the way in advancing early screening and proactive health management.
Antonio Reyes
CEO
Executive with experience as a Founder, CEO, COO, and Director of Business Development. He has forged strategic partnerships, led expert teams, and improved operational systems to boost revenue. Antonio grew BlockScience from 4 to 42+ employees and established partnerships with renowned institutions, achieving significant sales growth. He effectively communicates vision, direction & value propositions to all stakeholders.
Redefining the future of early screening and prevention with groundbreaking innovation.
Dr. Kyle H. Ambert
CTO
PhD in Biomedical Informatics. Dr. Ambert is currently the Director of Data Science at Nike’s Consumer Data Science division. Before Nike Dr. Ambert was the Senior Deep Learning Data Scientist at Intel. His responsibilities at Intel included Data Scientist roles in Artificial Intelligence & Applied Analytics Group, Health & Life Sciences: Big Data Solutions Group and Biomedical & Big Data Research.
Bringing AI and data into biotech and genetics is our most transformative achievement.
Scott Silverman
CFO
Scott, a financial executive with 25+ years of experience, excels in SME operational and financial management. He has diverse expertise in accounting, finance, legal, and operations, including SEC regulations. As President and CEO of EverAsia Financial Group, he grew the firm internationally. Scott has raised early-stage funds, taken five companies public, and earned recognition on Entrepreneur Magazine's “Hot 100” list. He holds a Bachelor's in Finance and a Master's in Accounting.
Smart financial leadership has been key to fueling our growth and advancing our mission.
Why invest in Revealia?
Why invest in Revealia?
01
Growing home screening market
02
First-mover advantage with RNA-focused tests
03
Clear path to Scalablity
Contact Us
Contact Us
Contact Us
Learn more about our journey and investment opportunities.
Learn more about our journey and investment opportunities.
Learn more about our journey and investment opportunities.
